Salem Investment Counselors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Salem Investment Counselors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-145	Closed	-$14K	–	1177
2023 Q4	$14K	Hold	145	–	–	﹤0.01%	755
2023 Q3	$12.8K	Hold	145	–	–	﹤0.01%	757
2023 Q2	$12.6K	Hold	145	–	–	﹤0.01%	787
2023 Q1	$14.1K	Hold	145	–	–	﹤0.01%	757
2022 Q4	$15K	Hold	145	–	–	﹤0.01%	707
2022 Q3	$12K	Hold	145	–	–	﹤0.01%	715
2022 Q2	$12K	Hold	145	–	–	﹤0.01%	749
2022 Q1	$11K	Hold	145	–	–	﹤0.01%	737
2021 Q4	$13K	Hold	145	–	–	﹤0.01%	784
2021 Q3	$11K	Hold	145	–	–	﹤0.01%	743
2021 Q2	$12K	Hold	145	–	–	﹤0.01%	688
2021 Q1	$11K	Buy	+145	New	+$11.8K	﹤0.01%	661

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Salem Investment Counselors's BMRN Position: Q1 2024 in Review

Salem Investment Counselors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 145 shares — an estimated $14K sold.

Salem Investment Counselors first reported a position in BMRN in Q1 2021 and held it in 12 quarters. The position peaked at $15K in Q4 2022. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Salem Investment Counselors reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Salem Investment Counselors sold 145 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $14K.
Salem Investment Counselors first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 12 quarters.
Salem Investment Counselors's BioMarin Pharmaceuticals position peaked at $15K in Q4 2022.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Salem Investment Counselors's 13F filing for Q1 2024, filed 11 Apr 2024.